F. Bostickbruton

Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy.

J. Yu, E. Reed, M. Dabholkar, 1994, The Journal of clinical investigation.

Cisplatin Induction of ERCC-1 mRNA Expression in A2780/CP70 Human Ovarian Cancer Cells*

K. Gardner, K. Gardner, B. Tsang, 1998, The Journal of Biological Chemistry.

Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells.

Q. Li, E. Reed, C. Mu, 2000, Anticancer research.

Cisplatin and phorbol ester independently induce ERCC-1 protein in human ovarian carcinoma cells.

B. Tsang, Q. Li, E. Reed, 1998, International journal of oncology.

Absence of evidence for allelic loss or allelic gain for ERCC1 or for XPD in human ovarian cancer cells and tissues.

Yian Ma, E. Reed, F. Bostickbruton, 2000, Cancer letters.

Increased mRNA levels of xeroderma pigmentosum complementation group B (XPB) and Cockayne's syndrome complementation group B (CSB) without increased mRNA levels of multidrug-resistance gene (MDR1) or metallothionein-II (MT-II) in platinum-resistant human ovarian cancer tissues.

E. Reed, M. Dabholkar, J. Vionnet, 2000, Biochemical pharmacology.

Ormaplatin sensitivity/resistance in human ovarian cancer cells made resistant to cisplatin.

E. Reed, J. Vionnet, F. Bostickbruton, 1993, Cancer research.